Veracyte (VCYT) CCO sells 13,975 shares under 10b5-1 plan, keeps 132K
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
VERACYTE, INC. Global Chief Commercial Officer John Leite reported an open-market sale of 13,975 shares of common stock on June 4, 2026 at a weighted average price of about $50.07 per share, executed under a pre-arranged Rule 10b5-1 plan. On June 2, 2026, 4,059 shares were withheld to satisfy tax obligations from vesting restricted stock units, which was not a market sale. Following these transactions, Leite directly holds 132,305 shares of Veracyte common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 13,975 shares ($699,732)
Net Sell
2 txns
Insider
Leite John
Role
Global Chief Commercial Off
Sold
13,975 shs ($700K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 13,975 | $50.0703 | $700K |
| Tax Withholding | Common Stock | 4,059 | $47.80 | $194K |
Holdings After Transaction:
Common Stock — 132,305 shares (Direct, null)
Footnotes (1)
- Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on June 2, 2026 and does not represent a sale. The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 9, 2025. Represents weighted average sales price. Sale prices for the transactions range from $50.00 to $50.30. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
Key Figures
Open-market shares sold: 13,975 shares
Weighted average sale price: $50.0703 per share
Sale price range: $50.00 to $50.30
+3 more
6 metrics
Open-market shares sold
13,975 shares
Common stock sale on June 4, 2026
Weighted average sale price
$50.0703 per share
Open-market sale on June 4, 2026
Sale price range
$50.00 to $50.30
Price range for June 4, 2026 sales
Tax withholding shares
4,059 shares
Withheld for RSU tax obligations on June 2, 2026
Tax withholding price
$47.80 per share
Value for tax-withholding disposition on June 2, 2026
Shares held after transactions
132,305 shares
Direct common stock holdings after June 4, 2026 sale
Key Terms
Rule 10b5-1 plan, restricted stock units, tax withholding obligations, weighted average sales price
4 terms
Rule 10b5-1 plan financial
"The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
restricted stock units financial
"in connection with the vesting of certain restricted stock units on June 2, 2026"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
tax withholding obligations financial
"withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting"
weighted average sales price financial
"Represents weighted average sales price. Sale prices for the transactions range"
FAQ
What insider transactions did Veracyte (VCYT) report for John Leite?
Veracyte’s Global Chief Commercial Officer John Leite reported selling 13,975 shares of common stock in an open-market transaction and a separate 4,059-share tax withholding related to vesting restricted stock units, leaving him with 132,305 directly held shares after these transactions.
Was John Leite’s Veracyte (VCYT) stock sale part of a 10b5-1 trading plan?
Yes. The filing states the reported transactions were executed under a Rule 10b5-1 trading plan adopted by John Leite on June 9, 2025, indicating the sale was pre-arranged rather than a discretionary, opportunistic market decision at the time of execution.